PAMP
ESPR

Polar Asset Management Partners’s Esperion Therapeutics ESPR Stock Holding History

Polar Asset Management Partners’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.77M Buy
+1,508,892
New +$4.22M 0.08% 287
2022
Q1 		– Sell
-105,551
Closed -$528K – 1310
2021
Q4 		$528K Buy
+105,551
New +$845K 0.01% 847

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Polar Asset Management Partners's ESPR Position: Q2 2026 in Review

Polar Asset Management Partners opened a new position in Esperion Therapeutics (ESPR) in Q2 2026: 1,508,892 shares worth $4.77M. The stake represents 0.08% of the portfolio and ranks #287 among its holdings. This is a return to the name: Polar Asset Management Partners previously reported a position in ESPR as recently as Q4 2021.

Polar Asset Management Partners first reported a position in ESPR in Q4 2021 and has held it in 2 quarters since. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Polar Asset Management Partners held 1,508,892 shares of Esperion Therapeutics worth $4.77M as of Q2 2026.
  • Esperion Therapeutics was a new Polar Asset Management Partners position in Q2 2026.
  • Esperion Therapeutics made up 0.08% of Polar Asset Management Partners's portfolio in Q2 2026, its #287 holding.
  • Polar Asset Management Partners first reported a position in Esperion Therapeutics in Q4 2021 and has held it in 2 quarters since.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Polar Asset Management Partners's 13F filing for Q2 2026, filed 14 Aug 2026.